Spyre Therapeutics CEO Turtle Cameron disposes of 15,000 common shares worth $1.31 million
SYRE•CEO sells shares in open-market transactions
- Spyre Therapeutics CEO Turtle Cameron sold 15,000 common shares on Sep. 1, 2026 at weighted-average prices of USD 86.36 to USD 89.07.
- Cameron’s direct holding fell to 552,540 shares following the transactions.
